Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Amcenestrant |
Trade Name | |
Synonyms | SAR-439859|SAR 439859|SAR439859 |
Drug Descriptions |
Amcenestrant (SAR439859) is a selective estrogen receptor degrader that down-regulates ER expression and signaling, resulting in tumor cell growth inhibition (Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-05, PMID: 31721572). |
DrugClasses | Hormone - Anti-estrogens 29 |
CAS Registry Number | 2114339-57-8 |
NCIT ID | C140354 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Amcenestrant | Abemaciclib Amcenestrant | 0 | 2 |
Alpelisib + Amcenestrant | Alpelisib Amcenestrant | 0 | 1 |
Amcenestrant | Amcenestrant | 0 | 6 |
Amcenestrant + Everolimus | Amcenestrant Everolimus | 0 | 1 |
Amcenestrant + Goserelin + Palbociclib | Amcenestrant Goserelin Palbociclib | 0 | 1 |
Amcenestrant + Letrozole | Amcenestrant Letrozole | 0 | 2 |
Amcenestrant + Midazolam | Amcenestrant Midazolam | 0 | 0 |
Amcenestrant + Palbociclib | Amcenestrant Palbociclib | 0 | 2 |